United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Sector average (own scale)
Sector average (own scale)
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for GT Biopharma, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|
| ROA | -499.37% | -517.97% | -742.31% | -742.35% | -742.44% | -742.73% |
|---|---|---|---|---|---|---|
| Total Assets | $7,124.00K | $3,816.01K | $3,816.01K | $3,816.01K | $3,816.01K | $3,816.01K |
| Sector average | $3,280,499.23K | $3,298,345.31K | $3,676,894.01K | $4,262,561.28K | $4,994,412.92K | $5,761,557.24K |
| Net Income | -$28,354.00K | -$28,333.07K | -$28,326.57K | -$28,328.29K | -$28,331.74K | -$28,342.77K |
| Sector average | $125,199.97K | -$3,170,058.36K | -$23,486,545.34K |
| -$23,692,765.65K |
| -$23,918,648.68K |
| -$24,600,837.95K |